Spruce Biosciences Inc
NASDAQ:SPRB

Watchlist Manager
Spruce Biosciences Inc Logo
Spruce Biosciences Inc
NASDAQ:SPRB
Watchlist
Price: 75.84 USD -2.77% Market Closed
Market Cap: 81.2m USD

Net Margin
Spruce Biosciences Inc

-6 869.3%
Current
-1 521%
Average
-6.4%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-6 869.3%
=
Net Income
-47.9m
/
Revenue
697k

Net Margin Across Competitors

No Stocks Found

Spruce Biosciences Inc
Glance View

Market Cap
81.2m USD
Industry
Biotechnology

Spruce Biosciences, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in Daly City, California and currently employs 15 full-time employees. The company went IPO on 2020-10-09. The firm is focused on developing and commercializing therapies for rare endocrine disorders. The firm's development product candidate, tildacerfont, is a non-steroidal therapy that offers disease control for patients suffering from congenital adrenal hyperplasia (CAH). Tildacerfont is a potent and selective, non-steroidal, oral, small-molecule antagonist of the corticotropin-releasing hormone receptor 1 (CRF1) receptor, which is a regulator of the production of adrenocorticotropic hormone (ACTH). Its CAHmelia-203, is a placebo-controlled, double-blind Phase IIb clinical trial in adult patients with CAH with poor disease control. Its CAHmelia-204, is a second Phase IIb clinical trial in adult patients with CAH with good disease control focused on glucocorticoid reduction. The company has also conducted two Phase IIa clinical trials of tildacerfont in adult patients with CAH on stable glucocorticoid therapy.

SPRB Intrinsic Value
116.42 USD
Undervaluation 35%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-6 869.3%
=
Net Income
-47.9m
/
Revenue
697k
What is the Net Margin of Spruce Biosciences Inc?

Based on Spruce Biosciences Inc's most recent financial statements, the company has Net Margin of -6 869.3%.

Back to Top